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Abstract
This paper compares and contrasts outpatient pharmaceutical policies for the elderly in
seven OECD nations: Australia, Canada, Germany, Japan, New Zealand, the United Kingdom,
and the United States.  Each country is facing an increasing financial burden due to rapidly
growing numbers of elderly citizens, in number and as a percentage of population, and rising
drug costs.  As a result, they are struggling to balance varying levels of commitment to providing
drugs for the elderly with the need to contain costs.  Although each country’s healthcare systems
are unique, the methods that each country is using to control rising pharmaceutical costs are
similar.  Many countries are gravitating towards the use of last-dollar rather than first-dollar
coverage.  All provide inpatient pharmaceutical coverage.
Introduction
Policies concerning prescription drug coverage for the elderly, here consistently defined
as over age 65, have recently become a pressing political issue around the developed world, as
the elderly population has grown, both in absolute number and as a percentage of the entire
population, and as the overall costs of prescription drugs have risen, due to increased prescribing
and the introduction of newer, higher priced drugs.  In this article we compare and contrast the
present policies regarding prescription drugs for the elderly in seven OECD nations:  Australia,
Canada, Germany, Japan, New Zealand, the United Kingdom, and the United States.  Our focus
is access to prescription insurance, extent of benefits coverage of insurance, and costs, both to
individuals and the entire nation.1
With the exception of the United States, the governments of the nations in this study are
struggling mightily with the challenge of maintaining their commitments to providing drug
coverage to the elderly while attempting to manage and control their costs.  What can the United
States learn from the ways the nations are coping with this challenge?  What lessons emerge for
the United States as it entertains the possibility of enhancing public elderly access to
pharmaceuticals by adding outpatient prescription drug coverage to its Medicare program?  We
conclude our comparison by speculating about these lessons, based on the international evidence.
We chose the seven countries that we did because they exhibit both interesting
similarities and differences in the ways Western nations are addressing access to and use of
pharmaceuticals among the elderly.  Indeed, one of the principal themes of our comparative
analysis is convergence.  This convergence is particularly apparent in the nations’ approaches to
cost containment applied to their prescription drug benefit; their shared strategies in this regard—
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which are employed in both the public and private sectors—include restricting drug coverage
through positive and negative lists, generic substitution, reference-based pricing, individual cost-
sharing, and more recently, the use of practice guidelines.  Japan is an outlier in that it has not
attempted to significantly restrict the consumption of pharmaceuticals and has maintained its
primary reliance on a strict pricing regulation scheme in order to control costs.  Though there is
more international variation in terms of elderly insurance access and coverage in the seven
nations, there is nonetheless a rough convergence of providing universal or near-universal access
to complete coverage for inpatient prescription drugs and last-dollar but not first-dollar coverage
for outpatient prescription drugs.  Here the United States is an outlier in that it provides
significantly less overall coverage for outpatient drugs through public sources, and does not
guarantee access to insurance for outpatient drugs.
Another principal theme is complexity of policy effect.  When the reader assesses the
elderly’s access, coverage, and costs from an international perspective, it is essential to recognize
that the final result for any citizen is the product of several different policies that are
simultaneously in force.  The ultimate effects of the policies are thus interdependent.  Policies
about out-of-pocket maximums, first-dollar versus last-dollar coverage, co-payments, co-
insurance, the use of positive and negative formulary lists, and so on, form a complicated web; as
each policy varies, it can have profound effects on the impact of another.  Individual policies can
further vary with different segments of the elderly populations, based on income or geographic
area for example.  The possibilities for variations in the web are endless in theory and multiple in
fact.  We have done our best to provide the reader with an accurate sense of the overall outcomes
of these webs of policies, but we are inevitably forced to be strand-specific in our attention.  We
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therefore caution the reader to recognize the complicated nature of the systems dealing with
elderly pharmaceutical coverage.2
Context and Background
Except for the United States, all seven nations have made a national commitment to
universal access to medically necessary hospital and medical services.  In all these nations except
Canada and the United States, this commitment includes access to prescription medications.3
And though the pressures of an aging population have caused deep reassessments of many social
insurance institutions, such as the pension system in Japan, the commitment to preserve
meaningful access to medically necessary prescription drugs for elderly citizens seems to be
firmly held.  The nations have largely protected their elderly drug support policies from
significant cuts in coverage, though there have been some increases in the share of costs borne by
the elderly.
Despite this commitment, there are dramatic variations among the nations in terms of
access, coverage, and costs.  These variations can extend to within the nations as well.  And
though there is a shared political stance in all of the nations, including the United States, of a
greater relative commitment to prescription drug access for the elderly than for the population as
a whole (evidenced in the United States by Medicare’s coverage of inpatient drugs), wide
international and domestic variations remain for this group as well.
The variations within nations are particularly pronounced in Canada and the United
States, two of the more federal governmental systems in the study.  In Canada, province of
residence and income drive the domestic variation in coverage for elderly citizens.  In the United
States, much more so than the other nations, income, wealth, past employment status, and type of
health insurance plan are the driving factors behind elderly access to and insurance coverage of
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prescription drugs.  The basic characteristics of each nation’s health care system and its policies
concerning elderly pharmaceutical coverage are summarized in Table 1.
As indicated in Table 2, spending on pharmaceuticals constitutes a large portion of the
nations’ total health care expenditures, and varies from a high of 20.8 percent in Japan to a low
of 8.8 percent in the United States.  The increase in spending on pharmaceuticals, which is not
shown in the tables, both in absolute and relative terms, has prompted a shared concern over the
future trends in pharmaceutical expenditures.  In Britain, for instance, pharmaceutical
expenditures increased by 80 percent between 1990 and 1996, and the proportion of total health
care expenditures constituted by pharmaceuticals—16.5 percent—is among the highest in the
European Union (Rosian, Habl, and Volger 1998).  While Japan has lowered the percentage of its
total health care costs spent on pharmaceuticals from a staggering 39 percent in the early 1980s,
pharmaceuticals still constitute over 20 percent of total health care costs, making it the most
drug-intensive nation in our study.4  The Japanese perform relatively fewer invasive health care
procedures in favor of more drug therapies.  Therefore the high proportion spent on drugs is
greatly offset by lower costs elsewhere.  In the United States, spending on prescription drugs only
constitutes about 9 percent of all health care spending.  But spending has been increasing at about
11 percent per year since the early 1990s, a more rapid rate of growth than for most other health
care sectors (Levit at al. 1998; GAO 1999) and, costs for other sectors such as hospital and
physician care are rising at even greater rates due to the use of more invasive procedures and
greater intensity of care than in other countries.
The different measures and relative rankings of expenditures on health care and
pharmaceuticals found in Table 2 emphasize different aspects of each nation’s economy and
health care and pharmaceutical policies, and tend to tell different stories.  Depending upon the
measure of expenditure the ranking of our seven countries in terms of health care and
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pharmaceutical expenditure will vary.  Simply comparing countries in terms of total or per capita
monetary expenditures in a single currency such as United States dollars will rank the wealthiest
country (United States) the highest, because United States citizens spend more per capita on most
commodities, not just health care (Deber and Swan 1999).
The measure of health expenditure most commonly used when making international
comparisons is the percentage of GDP (Gross Domestic Product), which is “defined as the sum
of total domestic expenditure plus exports of goods and services, minus imports of goods and
services. GDP closely resembles gross national product (GNP), differing primarily in its
treatment of investment income of nonresidents.  Health spending as a proportion of GDP
measures how much of the total economy is devoted to health care.”  Although widely used in
debate, there are limitations of presenting health care expenditure as a percentage of GDP.
“Spending as a proportion of GDP reflects not only how much is being spent for health services
but also the health of the economy” (Deber and Swan 1999).
Purchasing Power Parities (PPPs) are the rates of currency conversion that allow the
purchasing power of different currencies to be expressed in a common unit.  A PPP is computed
as “the sum required to buy the same basket of goods and services in each country if everyone
had to pay the same prices” as a reference country (the United States in Table 2). An advantage
of PPPs over nominal expenditures per capita is that they eliminate “differences in price levels
among countries so that international variations reflect only differences in the volume of goods
and services purchased” (Deber and Swan 1999).
In terms of elderly individuals’ spending on pharmaceuticals, because most of the nations
employ last dollar coverage rather than first dollar coverage, the out-of-pocket costs for
prescription drugs can be considerable, even with the presence of universal programs.  It should
be noted that Japan is the exception here, with essentially both first and last dollar coverage—
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extremely small drug co-pays, and no premiums—for those over 70 years of age.  Among
Medicare beneficiaries in the United States, where there is no universal program and where the
elderly consume a third of all prescription drugs, the estimates for individual yearly out-of-pocket
expenditures for prescription drugs range from $300 to almost $600 (see Soumerai and Ross-
Degnan 1999; Davis et al. 1999; Rother 1999; Gibson et al. 1999).
The demographic picture adds to the problem of elderly pharmaceutical expenditures.  As
Table 3 demonstrates, although the seven nations vary significantly in the percentages of their
populations over 65, they are all rapidly aging.  By 2020, for example, over a quarter of the
Japanese population will be over 65; also note in this regard that Japan already spends one third
of its total health care budget on the elderly (Graig 1999).  The decline in the nations’ ratios of
workforce population to the population over 65 exacerbates the problem; once again, Japan
provides a dramatic example.  It is interesting to note that in comparison with the other six
nations, the United States is relatively young; indeed, in 20 years it will be only slightly older
than Japan is now.  Nonetheless, for all seven nations, the combination of present drug
expenditure levels and future demographic profiles suggest a potent combination for increased
drug expenditures in the coming years.
Demographics are not the whole story behind the rise in health care and drug
expenditures, however.  For example, in Japan between 1980 and 1990, the number of those over
65 increased by 32 percent, but there was only a 1.6 percent increase in the proportion of GDP
accounted for by health care costs.  In addition the percentage of total health care costs accounted
for by pharmaceuticals dropped from 39 percent in 1981 to 26 percent presently, largely due to
strengthened price controls (Ikegami and Campbell 1999; Graig 1999).  In contrast, in the United
States, the increase in those over 65 was only 10 percent, but the proportion of GDP accounted
for by health care costs rose by 32 percent (Oliver et al. 1997).  Also note that over the past 20
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years in the United States, health care expenditures for the elderly have outpaced the growth in
GDP by 3 to 4 percent, while the number of elderly has been growing only about 1 percent per
year faster than the entire population.  In the United States new technologies, including new drug
therapies, are responsible for most of the increase in elderly health care costs (Fuchs 1998).
Access to Insurance for Pharmaceuticals Among the Elderly
Table 4 provides an overview of the publicly provided access to and coverage of
pharmaceuticals for the entire nation and for the elderly population.  All the nations in the study
provide essentially universal access to inpatient prescription drugs for the elderly.  Four of the
nations—Australia, Britain, Japan, and New Zealand—provide publicly funded prescription drug
coverage, both inpatient and outpatient, to the entire population.  In Germany, Canada, and the
United States, the situation regarding elderly access to insurance is more complicated, and
requires further elaboration.
Elderly outpatient prescription drug coverage in Germany is similar to that for the entire
population; most pharmaceuticals are covered by the public plan.  Elderly citizens do not receive
exemptions from or reductions in co-payments.  Up until the past decade, the German health care
system offered health care through a uniform sickness fund system.  Over 1,354 funds existed
until about 1992.  Every fund offered the same benefit package, and membership was
compulsory for the public.  The sweeping reforms of 1993 (Health Sector Act-GSG) proposed
changes to the sickness funds in 1996, which included allowing patients to choose between
sickness funds, and encouraged competition among sickness funds.  One of the more immediate
results of these reforms was the reduction of the number of sickness funds to 482 by 1998.  As
well, sickness funds must adjust fund revenues to account for the risks of those who subscribe to
their fund.  Sickness funds operate under strict national regulations, as self-governing health
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insurance funds, who contract selectively with physicians and hospitals to provide care. (Brown
and Volker 1999; Schulenburg 1997; Rosian et al. 1998).
In Canada, all elderly citizens with financial need have at least some insurance coverage
for outpatient prescription drugs through provincial drug programs.  Two of Canada’s ten
provinces restrict public drug coverage to low income elderly.  One of these, though, provides a
subsidy for the elderly toward purchasing private insurance.  Three provinces provide the same
levels of coverage to all elderly residents; the remainder have coverage for all elderly but means-
based variation in cost sharing.  Twenty-two percent of elderly Canadians have some form of
private drug insurance as well, usually as retiree benefits from their former employers.  The
overall landscape in Canada is thus one of patchwork coverage, driven in some cases by financial
need (Willison, Grootendorst, and Hurley 2000).
In the United States, the terrain is considerably more uneven, with excellent coverage in
some instances and the absence of coverage, regardless of financial need, in others.  Essentially
all elderly citizens have inpatient drug coverage through Medicare.  The system of insurance for
outpatient drugs, however, is quite fragmented, and includes both public and private sources,
Medigap plans and managed care, and means-tested and non means-tested programs.  The
publicly funded sources of access are further fragmented by level of government—there are
separate assistance programs at the national, state, and (some) municipal levels.  Most of the
public drug assistance programs are means-tested.  These different insurance mechanisms also
vary widely in their coverage.
In the United States, a little over one-third of all elderly persons have no coverage
whatsoever for outpatient drugs; the others have varying levels of coverage through employer-
sponsored retiree plans, privately purchased “Medigap” plans, the means-tested national
Medicaid and Veterans benefit programs, connection with the Defense Department, participation
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in a Medicare managed care program (in recent years, the elderly have had the option of
receiving their Medicare-based health care through managed care organizations, and most of
these offer outpatient drug benefits not included in the traditional fee-for-service Medicare plan),
and state and even municipal drug access programs (Gross and Bee 1999; NPC 1998).
Elderly persons can, and do, participate in more than one of these options, and thus
obtaining relative numbers on enrollments is problematic.  One study using 1995 Medicare
survey data (the most recent available) attempted to place beneficiaries in single categories based
on “their primary source of [supplemental health insurance] coverage” for that year, and
generated the following percentages of coverage:  35 percent with no drug coverage; 6 percent
HMO; 11 percent Medicaid; 27 percent employer-sponsored; 8 percent individually purchased; 2
percent other (Davis et al. 1999).  In addition, 6 percent switched their primary source of
coverage during the year.  The remainder, 3 percent, received their drug coverage through an
insurance source other than their primary supplemental health insurance (the total is less than 100
percent due to rounding).  That study did not take into account state and city drug assistance
plans.  Less than half the low-income elderly, however, live in states with these assistance
programs (Soumerai and Ross-Degnan 1999).
Since 1995, additional Medicare beneficiaries have joined Medicare managed care
HMOs.  Fifteen percent of all Medicare beneficiaries (6.3 million) are currently enrolled in these
plans.  Somewhere between 80 and 95 percent of the plans offer outpatient prescription drug
coverage, though there are recent reports of HMOs dropping this coverage, and the extent and
nature of the coverage varies widely (Davis et al. 1999; Barents Group 1999).  Medicare HMOs
are most prevalent in the West.  Since HMO penetration is far shallower in rural areas than
elsewhere, elderly persons located in rural areas are less likely to have coverage through a
Medicare HMO.  In addition, those plans that do exist in rural areas are approximately four times
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less likely to offer drug coverage than plans in urban areas; indeed only 4 percent of Medicare
beneficiaries in rural areas have access to a Medicare HMO with drug coverage (HCFA 1999).
Eighty-eight percent of the elderly in Medicaid receive outpatient prescription drug
benefits (Davis et al. 1999).  Only 3 of the 10 existing standardized Medigap plans offer any drug
benefits at all (plans “H,” “I,” and “J”), covering 29 percent of all plan holders.
Fourteen states currently offer their own pharmacy assistance programs, primarily for
those who are low-income but who do not qualify for Medicaid, or for those who spend a
disproportionate percentage of their income on prescription drugs.5  The plans vary widely in
coverage.  In addition to the state programs, there are several city and municipality programs—
for example in Boston, Massachusetts, Seattle, Washington, and Austin, Texas, and the county
surrounding it—adding further to the fragmented nature of the United States system.  But
apparently, no comprehensive listing of such programs exists.6
There is also the possibility that unions and religious organizations offer outpatient
prescription drug assistance.  There have been reports of such coverage, but we have yet to find
reliable systematic data on it.  There are other programs of various kinds.  Some pharmaceutical
corporations, for example, have programs to provide free drugs to eligible persons, and the
political interest and research group American Association of Retired Persons (AARP) has a
Pharmacy Service Program that arranges for discounts on drugs.7
Coverage of Pharmaceuticals Among the Elderly
Public/Private Mix
In all countries studied, inpatient pharmaceutical expenses are fully covered under
national Medicare programs.  Outside the institutional environment, countries vary somewhat.
The United Kingdom, Australia, and New Zealand have publicly financed national pharmacare
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programs for all citizens.  In Germany, all citizens have access to public coverage through a
collection of sickness funds, with similar coverage for pharmaceuticals.  About 10 percent of the
German population—predominantly non-senior high income earners—has opted for private
coverage.  Canada and the United States are notable in the extent of private sector coverage for
pharmaceuticals.
In Canada, approximately 87 percent of all residents regardless of age have some form of
coverage for pharmaceuticals.  Approximately 25 percent are publicly funded (primarily the
elderly and those on social assistance), and another 62 percent have some form of private
coverage.  However, public system in Canada offers some form of coverage for almost all (98
percent) of its elderly population, albeit with widely varying cost-sharing provisions.  In addition,
private coverage may extend to the elderly to the extent that former employers may cover their
retirees for medications not covered on the positive lists of public plans.  In this regard, the
private sector is the payer of last resort.
As detailed in the previous section on access, given the patchwork and overlapping nature
of coverage in the United States, it is difficult to provide a detailed breakdown of public versus
private coverage.  Roughly 35 percent of elderly persons have no coverage for outpatient
prescription drugs.  Roughly 25 percent have public insurance coverage through Medicare
managed care and Medicaid and roughly 40 percent have private insurance coverage (Medigap).
The extensiveness of the coverage varies dramatically from state to state, particularly with
private insurance.  In Japan, all residents have the same extensive government-mandated
pharmaceutical benefits, and receive them through employer-based or government based
insurance plans.
In those countries with national pharmaceutical programs, reciprocity agreements are in
place that allow for portability across jurisdictions (i.e., equivalent coverage, if the jurisdiction in
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which a prescription is filled differs from the place of residence).  In Canada, a senior filling a
prescription in a different province would follow the rules of the province in which the
prescription was dispensed.  Portability in the United States varies widely and depends on the
plan of coverage.
Funding, Costs and Cost Containment
The seven nations vary widely in their matrices of funding for elderly pharmaceuticals,
but all employ some combination of public sources and individual out-of-pocket sources; in
Canada and the United States there is a heavy reliance on private third-party insurance as well
(see Tables 2 and 4).  The complicated nature of the funding mechanisms across different
countries makes it difficult to know precisely what the overall distributions of individual
expenditures in each nation are, but it is likely the case that the more uniform, national, and
public the funding effort is, the more consistent and more progressive the overall funding burden
will be.  This suggests that nations like Britain, Japan, and New Zealand have the most
progressively funded systems.
Once again, the United States is the outlier, with an overall funding scheme that is quite
fragmented and on the whole relatively regressive and reliant on out-of-pocket expenditures.
Because of its fragmented nature, it is difficult to capture this completely, but the following
figures offer some glimpse of the relative burdens placed on the elderly in their consumption of
outpatient pharmaceuticals.  According to one AARP study, prescription drugs account for
almost one-fifth of the out-of-pocket spending for all health care by Medicare fee-for-service
beneficiaries (Gross et al. 1998).  According to another study, all Medicare beneficiaries spend
$303 per year on drugs; those without drug coverage spend $432.  Those with HMO drug
coverage spend $162; those with employer-sponsored drug coverage spend $224; and those with
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Medigap drug coverage spend $361 (Davis et al. 1999; see also Lillard et al. 1999).  A second
study placed the out-of-pocket drug costs for Medigap beneficiaries much higher, at $570 per
year, and estimated the costs for those with no coverage whatsoever at $590 (Rother 1999).  A
third estimated the current out-of-pocket prescription drug cost for all noninstitutionalized
Medicare beneficiaries at $410, and 4 percent of income.  For those without drug coverage, these
respective figures were $590 and 6 percent; for those with some type of coverage, $320 and 3
percent (Gibson et al. 1999).  Note that none of these sets of figures takes into account insurance
premiums, which are high for Medigap plans and low for Medicare HMOs (in 1997 70 percent of
Medicare HMOs charged no premium at all [Graig 1999]), nor the fact that those with better
coverage take more drugs, except for those in HMOs (Davis et al. 1999; GAO 1999).
Regarding the spending on drugs by income level and as a percentage of income, the
patterns are similar.  One recent AARP study estimated that Medicare beneficiaries with incomes
between 135 and 200 percent of the poverty level (about $10,900-$16,150) spend the greatest
amount out-of-pocket on drugs—$445 on average.  As a percentage of income, those in the
poorest category, with incomes under the federal poverty level, spend the most—9 percent of
income (or $310).  And those below poverty levels who do not receive Medicaid benefits spend
13 percent of their incomes ($400).  In contrast, those with incomes between 200 and 400 percent
of the poverty level spend only 3 percent of their income ($425), and those above 400 percent of
the poverty level spend just 2 percent ($405) (Gibson et al. 1999).  Another AARP study of fee-
for-service Medicare beneficiaries found that those with annual household incomes below
$10,000 spent 8 percent of their income on prescription drugs; those with incomes above $25,000
spent 2 percent (Gross et al. 1998).  Again, these studies do not take into account the fact that
those with lower incomes buy fewer drugs.
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There is considerable convergence across countries in approaches to cost-containment.
Strategies include: restricting drug coverage (through positive and negative lists), use of practice
guidelines, generic substitution, reference-based pricing, and user cost-sharing.
Formularies
A hallmark of publicly funded pharmacare programs has been the use of positive and
negative lists for drug coverage.  All countries but the United Kingdom and Germany make use
of positive lists, also known as formularies.  Positive lists describe pharmaceuticals that will be
paid for by the insurer.  The United Kingdom and Germany make use of negative lists (i.e., drugs
that will not be paid for by the insurer).  The default assumption is that, should a drug receive
approval for marketing in the country then, unless an exception is made, the public insurer will
cover that product.  Functionally, the end result is equivalent from the perspective of the
consumer.  In Germany, recent attempts to introduce a positive list of reimbursable drugs have
been blocked by the lobbying of the pharmaceutical industry, as have attempts to substantially
expand the negative list of drugs (Tuffs 1999).
Practice Guidelines
Formularies generally provide a wide scope of prescribing freedom within the bounds of
pharmaceuticals covered and generally cover the watershed of treatment options.  New
pharmaceuticals, however, provide a substantial challenge to pharmaceutical budgets and to the
formulary system.  The entry prices of new pharmaceuticals are substantially greater than those
of the older generation of drugs with which they compete.  However, there is often a clinical
advantage that would justify their use in limited circumstances.
An increasingly popular mechanism for dealing with such discretionary use
circumstances is the use of clinical practice guidelines.  Clinical practice guidelines are, in
essence, authoritative statements of best practice in the management of specific medical
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conditions.  They have been in existence in one form or another for decades.  Developed to
reduce practice variation and control costs, guidelines find their origins in institutional settings.
In the past decade, they have been used increasingly in public pharmacare plans to complement
the formulary system.  Whereas formularies manage budgets through inclusion or exclusion of
specific products, practice guidelines allow for greater discretion on the part of the prescriber
while still restricting use through supply side measures.  They have been applied chiefly to limit
use of second and third line therapies for clinical or economic reasons.
Guidelines are used in Australia, New Zealand, and the United Kingdom in setting
pharmaceutical reimbursement policies for expensive new medications.  They are being
employed increasingly in Canada by provincial governments, and are in common use in the
United States by managed care organizations.
In the past, it was common to develop guidelines through consensus conferences of
leading physician specialists.  In recent years, there have been substantial changes in the
development of guidelines.  It is increasingly common that guidelines are developed with explicit
reference to the “best evidence” on effectiveness and efficiency, incorporating input from
epidemiologists, statisticians, and economists.  The incorporation of formal economic analysis
techniques was pioneered in Australia and Canada (Guidelines for Economic Evaluation for
Pharmaceuticals, Canada 1994; Guidelines for the Pharmaceutical Industry on Preparation of
Submissions to the Pharmaceutical Benefits Advisory Committee, Australia 1992), and now play
a major role in the approval of new drugs in the United Kingdom, through the newly created
National Institute for Clinical Excellence (NICE).  The success of practice guidelines in limiting
the use of targeted drugs is dependent upon the effective dissemination of practice guidelines and
the mechanisms employed to ensure compliance with recommendations, and has been the subject
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of numerous reviews (e.g., Grimshaw et al. 1995; Woolf et al. 1997; Haycox, Bagust and Walley
1999; Hurwitz 1999; Feder et al. 1999; Davis and Taylor-Vaisey 1997.)
Generic Prescribing and Reference-Based Pricing
Generic drugs are chemically identical “copies” of pharmaceuticals with expired patents.
In most countries, physicians must prescribe by generic name in order to allow the dispensing of
a generic product to be dispensed.  Generic prescribing is promoted by all public insurers studied.
In Canada, provinces are legally authorized to automatically substitute a generic equivalent, if
available, even if the prescription is written for a name-brand product.
Reference-based pricing carries substitution one step further by declaring drugs in
particular therapeutic classes as equivalent, and setting reimbursement at either the lowest price
or the average among therapeutically equivalent products.  Some form of reference-based
prescribing is employed in Australia, New Zealand, and Germany.  One province in Canada has
introduced reference-based pricing, and it is used in the United States by some pharmaceutical
benefits managers and some managed care organizations.  However, policies vary substantially
across countries in terms of therapeutic categories of drugs selected, inclusion of patented
medicines, and the selection of the reference price.
Cost Sharing
While the above methods of cost-containment have focused on supply-side measures,
considerable attention has gone into demand-side management and cost-control through
consumer cost-sharing.  Cost-sharing can take two basic forms: (1) deductibles, which require
that the beneficiary pay the full cost of drug expenses up to some pre-specified amount; and
(2) co-payments.  Copayments come in two forms: a flat indemnity payment, which requires that
the beneficiary pay a fixed charge per prescription; and co-insurance, which requires that the
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beneficiary pay a specified proportion of the cost of the prescription (applied to the drug
ingredient cost alone, the dispensing fee alone, or both).
While all countries studied employ cost sharing in some fashion, there is considerable
variation across countries in which of these methods is employed, and the criteria used (see
Table 4).   In addition, there is large within-country variation in cost sharing provisions in
Canada and the United States (Willison, Grootendorst, and Hurley 2000; Barents Group 1999).
In all countries, cost sharing has increased in the past decade.  With the exception of the United
States, countries generally limit consumer cost sharing, consistent with the principles of true
insurance.  Australia, Japan, and several provinces in Canada provide substantial reductions in
cost-sharing for the elderly while, in the United Kingdom, the elderly are exempt from cost
sharing.  In New Zealand, reductions in cost sharing are based on high use of chronic
medications, many of which are used largely by the elderly.
Other Strategies
Physicians in the United Kingdom, Germany, and New Zealand have prescribing budgets.
Until recently, in the United Kingdom, these budgets have been virtual budgets with no tangible
consequence if surpassed.  With the conversion to primary care groups (and eventually primary
care trusts) physicians now hold “hard” budgets for pharmaceuticals that are unified with budgets
for other primary and secondary care services (Majeed and Malcolm 1998).  A similar attempt in
Germany to hold physicians financially accountable for prescribing budgets in the early 1990’s
was reversed within two years of introduction and recent attempts to re-introduce strict budgets is
being met with resistance from physicians (Tuffs 1999; Busse and Howorth 1996).  While there
is some evidence that pharmaceutical budgets in the United Kingdom increase the prescribing of
generic drugs and slows the increase in drug costs, the long-term cost-effectiveness of this
strategy has not yet been evaluated (Wilton and Smith 1998).
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Conclusion—Lessons for the United States?
The Western nations that have most reliably provided access to pharmaceuticals for their
elderly populations have combined a universal access approach with catastrophic or “last-dollar”
coverage for outpatient prescription drugs, and some strong mechanisms of cost control in
addition to individual cost-sharing.  The convergence in their policies illustrates their collective
struggle to control costs.
If the governing process in the United States arrives at the decision to publicly guarantee
for the elderly meaningful access to outpatient prescription drugs—an idea that the public
apparently supports—then it will presumably be pushed toward adopting cost containment
policies similar to those described earlier.  Adding public outpatient prescription drug coverage
for the elderly is expensive—there is no getting around this fact.  The other six nations in this
study offer a set of choices for attempting to control the considerable expense involved.  These
are hard choices indeed for governments to make, but something significant must be done to
address the problem of costs.
President Clinton’s current proposal to add outpatient prescription drug coverage to the
Medicare program only taps access and does not include last-dollar coverage.  Furthermore, his
proposed plan has voluntary rather than mandatory participation.  Individuals opting for the plan
would have half of the cost of their prescription drugs reimbursed, up to a maximum of $1,000 in
the first year, and rising to $2,500 by 2008.  Premiums would be $24 per month in 2002, and
would rise to $44 in 2008; however, the premiums and copayments are waived for those
Medicare beneficiaries with incomes under 135 percent of the poverty level, while those between
135 percent and 150 percent would get a partial subsidy.
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President Clinton’s plan is obviously tailored to fit into the presently existing fragmented
system of elderly drug coverage.  It has no significant cost containment strategy, other than the
sizable portion of individual cost-sharing (which of course diminishes the extensiveness of the
coverage).  Thus, this reform, like all other United States health care reforms, seems to be stuck
in the following dilemma:  Anything significant and drawing on the best available lessons from
the international experience appears to require a fundamental restructuring of the overall system,
and in particular the adoption of last-dollar coverage and strong cost control policies—a course
that is apparently not politically viable.  But any politically viable reform can do little to
fundamentally change the problems of access, coverage, and cost that are deeply lodged in the
present American system.  This plan will likely help, in that it will bring some drug coverage to
some additional elderly persons, but that is about all that can be said for it.  Congressman Wilbur
Mills once described most policy activism in the United States as “leaning forward in the
foxhole.”  This reform appears to qualify for his definition.
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Endnotes
1. Among the important topics we are largely setting aside in our inquiry are the effects of
public policies on industrial development, corporate incentives, and pharmaceutical
research and development, price, and the effects on access, cost, and coverage of changes
in the corporate sector.  In particular, how prices are set is a very complex subject and
beyond the scope of this paper.
2. The reader is further cautioned that terms like “out-of-pocket,” “cost-sharing,” “co-
payment,” “co-insurance,” and “maximum payment” are not used consistently among
publications concerning pharmaceuticals, and therefore our descriptions that are based on
others’ research contain some inherent uncertainty.  For example, it is usually the case
that “out-of-pocket” costs do not include spending on over-the-counter medications,
particularly in European publications.  They also do not typically include the cost of
premiums.  This is not always the case, however.  We have attempted to be as clear as
possible in this regard.  We have also included a glossary of terms appearing at the end of
this article.
3. In Canada, pharmaceuticals are not covered under the national program.  Instead, each
province has introduced its own eligibility criteria for publicly funded Pharmacare,
resulting in a mix of public and private insurance under which approximately 25 percent
of its citizens and 48 percent of filled prescriptions are covered publicly.  Approximately
62 percent of the citizens have some form of private drug insurance coverage and about
11 percent have no coverage, either public or private. (Dingwall 1997)
4. Japan’s high percentage is driven both by its high consumption of pharmaceuticals and its
lower expenditures in other health care areas.
5. The states are:  Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts,
Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Wisconsin, and
Wyoming.
6. Information on the municipal programs was collected through phone conversations with
individuals in those locations.  Additionally, information on the existence of assistance
through unions and religious organizations was gathered anecdotally and no corroborating
written material was available.
7. Information on AARP’s pharmacy program is available at http://www.rpspharmacy.com.
Table 1.    Healthcare and Pharmaceutical Background for the Seven Selected Countries
Healthcare Systems Pharmaceuticals and Prescribing
Australia
Australia guarantees universal access to health care, called Medicare, regardless of
ability to pay.    It is financed by general taxes, and an income related Medicare levy
(averaging 1.5% of taxable income, depending on income, marital status etc.).  The
national government (Commonwealth) funds most non-hospital medical services,
pharmaceuticals and health research.  Grants from the Commonwealth to the States and
Territories fund public hospitals, home, and community care for the aged.  There are 44
registered health insurers offering private health insurance.  A community rating system
is used.  Private insurers cannot insure non-hospital services covered by Medicare.
Private insurance is used to provide benefits additional to Medicare, such as choice of
doctor, private room in hospital etc.  The public sector provided 61% of hospital
facilities in 1996/97.  Patients may choose to be private patients in public hospitals, or
private patients in private hospitals.  From 1990 to 1998, the percentage of the
population covered by private insurance for hospitals has declined from 45% to 31%.
Public hospitals have pharmacies, which provide medications to in-patients for free, and
do not fall under the Pharmaceutical Benefits Scheme.  Over 90% of people aged 65
years or more had some private insurance.  Privately owned nursing homes provide the
majority of long-term care for the elderly.
General:  Australia’s national reimbursement scheme for pharmaceuticals
is called the Pharmaceutical Benefits Scheme, with the objective of
providing access to essential drugs for all Australian residents.  The PBS
was introduced in 1953.  Australia uses a ‘positive’ list, or formulary,
which describes the drugs that a resident can expect to have covered
publicly.
Cost sharing: Under the PBS, Medicare eligible patients who do not hold
a Health Care Card, Pensioner Concession Card or Commonwealth
Seniors Health Card, pay up to the first $20.00 for each prescription item,
and co-payments are capped at $612.60 within a calendar year. Patients
who hold a concession card pay $3.20 per prescription item. For
concessional and pensioner patients (cardholders), once their total eligible
expenditure exceeds $166.40 within a calendar year, any further
prescriptions are free for the remainder of that year. All pensioners have
their pensions supplemented by a pharmaceutical allowance of $140.40.
A combination of generic based substitution and reference based pricing
is used.
Canada
Since 1965, Canada has had a universal access single-payer health insurance system,
called Medicare. Approximately 92% of citizens are covered by universal health services.
Funding for Medicare varies by province, with mixed tax, employer tax, and premium.
Provinces are the sole payers for all services deemed “medically necessary,” the definition
of which varies within each province.  While private insurers exist, they can only provide
coverage for services not paid for by the government.  Each province has its own plan.
Patients have choice of providers.
General:  Canada does not have a national pharmaceutical program, for
citizens in general, nor for the elderly.  Such programs are the
responsibility of each of the 10 provinces.
Cost-sharing:  Each province has discretion for cost-sharing policy, and
thus co-payments are highly variable across provinces.  Four provinces
have universal coverage, and over 60% of all Canadians have some sort
of private insurance plan.  One province has adopted reference based
pricing.
Table 1.   Continued
Healthcare Systems Pharmaceuticals and Prescribing
Germany
The national Medicare system in Germany is operated by the Statutory Health Insurance
Organization (GKV). 88% of the population is enrolled in the GKV.1 Individuals receive this
medical coverage by belonging to one of the 482 ‘sickness funds’.  The Federal Government
regulates this system, which is implemented by the 16 regions (Landers).  80% of health care is
funded by social security or taxes, through contributions from both employers and employees and
delivered by both public and private providers. .  The sickness funds negotiate with providers and
collect payments from individuals.  Over the past decade, policy has generally been focused on
attempting to encourage competition.  Approximately 9% of  Germans have private insurance
coverage, mostly held by high-income earners who opt out of the statutory public system to receive
some additional benefits through the private system.  Almost all family physicians are contracted
with the GKV.  57% of beds are provided by public hospitals, 37% of beds are owned by the
German Red Cross (nonprofit) or churches.  The hospital levy was eliminated in 1999.
General:  Sickness funds contracted with the GKV pay for all
physician-prescribed drugs, except those on the negative list,
which was implemented in 1983, and then added to in 1991.  This
list includes cold remedies, somatotherapies, laxatives, and
motion sickness.  A positive list had been proposed in the early
1990s by the government, but was not implemented.   A positive
list has recently been proposed again, and is receiving serious
consideration.
Cost-sharing: Patient co-payments doubled in 1997, but are still
comparable to other European countries, and have recently been
reduced.
United Kingdom
The National Health Service (NHS), introduced in 1948, provides universal access to health
services for all citizens. Public and private providers ‘compete’ for contracts with the 100 District
Health Authorities.  Almost all health care services come from public services and are financed
by 83.5% from taxes, 4% patient copay,  and 12.5% social security.  Reforms in the early 1990s
attempted to bring about more competition between providers.  More recently, the emphasis has
been on coordination and quality services. Only about 10% of the population has private
insurance, which is used mostly for supplementary coverage.  Since 1991, public hospitals are
self-governed and privately administered ‘Trusts’.  The UK moved rapidly from a public to
private system for long term care in the latter 1990s, with over 70% of long-term care now
occurring in independent homes.
General:  All prescribed pharmaceuticals are reimbursed by the
NHS, except for those on the Selected List Scheme (negative list).
The negative list of approximately 2,000 products includes
antacids, analgesics, medicine for coughs and colds, laxatives etc.
Cost-sharing:  There is a 5.8 pound co-payment per prescription
item, with extensive exemptions in place for various populations.
All elderly are exempt from co-pays. As the fund-holding budgets
for prescribing became fixed in 1999 , universal or near-universal
coverage of prescriptions offered by the District Health
Authorities is likely to decline.
Table 1.    Continued
Healthcare Systems Pharmaceuticals and Prescribing
Japan
Japan’s universal access health insurance system is a mixture of employer mandate
insurance and government programs for the employees of small firms, the self-
employed, pensioners, the unemployed, and the poor. Individuals cannot opt out of
the mandated system. It is an all-payer system in terms of price regulation, and is
funded through employer and individual premiums, which are based on income, and
tax revenues.  Funding sources for the health care system:  12% out of pocket; 57 %
insurance contributions (employer and individual premiums; employer must pay at
least 50%, but in practice is as much as 80%); 37 % from government subsidies.
When the government mandated transfers of funds from employer insurance
contributions to other insurance programs are counted as government sources, about
half of total costs from government Pensioners (retirees), self-employed, poor,
unemployed, in Japan are covered through municipality-based Citizens’ Health
Insurance [CHI].  All those over 70, and over 65 if bedridden, are covered by Health
Services for the Elderly (Roken). Premiums in the employer-sponsored insurance
schemes vary widely by employer, as do the premiums for one of the government-
sponsored schemes (the municipality-based Citizens' Health Insurance [CHI]),
depending on the demographics and income of the city.
Public Plans:
100% coverage by either government mandate employer-based insurance or
government programs.
No additional premiums for drugs.
For those in CHI, premiums vary depending on income, assets, and household
size, and with income and demographics of the city—a community rating
system based on municipality.  Maximum is about $430 per month per
household (in 1996 average annual household premium was $1,140.  An
approximately $450/month maximum on out of pocket payments.  Pay 30
percent of costs out of pocket; 20 percent if retired.  All costs over about $530
per month are fully covered by plan.  But these maximums are lower for lower
income and chronically ill.
These co-payments are for the doctor visit that produces the prescription;
There is no separate co-payment for the drug.
For those over 70, the health care, including drug benefit is completely free to
the patient.  There is a small co-payment for the doctor visit that produces the
prescription; 500 yen per outpatient visit (about $4).
New Zealand
Medicare: In New Zealand, a single Health Funding Authority funds health
services.  The HFA contracts with both public and private providers. The system is
financed through taxes (77.1%), out of pocket (16.%)and private insurance 6.2%.
Over 40% of the population has private, non-tax deductible health insurance
(mostly upper income), and is used to cover co-payments and supplementary
services.  Private insurance only accounts for 7.1% of total health expenditures.
Publicly owned hospitals provide most of the secondary care.  Private hospitals
provide long-term geriatric care and elective surgery.  Primary care is provided by
publicly-funded but privately owned general practices.  Over 50% of GPs in New
Zealand are in some form of budget holding arrangements, which are mostly
restricted to pharmaceuticals and lab tests. New Zealand introduced contracts and
competition in 1993, but has recently merged the 4 regional health authorities back
into one large national funding authority.
General:  The Pharmaceutical Management Agency Limited (PHARMAC), is
a non-profit company owned by the HFA, which was created in 1993.  It
manages the national Pharmaceutical Schedule (positive list).  The positive list
describes the price of each drug listed, and how it will be reimbursed from
public funds.
Cost sharing:  Various combinations of high use and community services card
holders allow reduced or no co-payment.  Children under 6 are free.  Adults
who are not card-holders pay $15, or the price of the prescription.
Table 1.    Continued
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United States
General: Healthcare in the United States is funded through a combination of public and
private sources, and has often been described as a “patchwork” of different systems in
terms of both delivery and financing.  On average, 85% of Americans have private
and/or public health insurance.  60% of the population has private insurance.  Around
10% of the population, generally low-income individuals are covered by Medicaid.
15% of the population has no health insurance.
Private:  Most services are privately delivered.  While traditionally this system was
based on a fee-for-service model, there has been a marked transition to managed care,
particularly in the last decade.  The majority of Americans obtain health insurance
through employer-based systems.  Very low-income individuals, low-income children,
and the disabled are eligible for Medicaid, a publicly funded insurance program.
Elderly:  All Americans over the age of 65 are eligible for Medicare, the federal health
care program for senior citizens, which covers inpatient and outpatient acute care and
inpatient pharmaceuticals.
General:  Approximately 65% of Americans have prescription drug
coverage through private plans, Medicaid, purchased Medigap
policies for the elderly, and state and municipal programs.  Medicare
does not cover prescription drugs, though some elderly receive
prescription drug benefits through Medicare HMOs.
Cost Sharing: The level of cost-sharing between insurance plans
and individuals is highly variable.  Individuals with no prescription
drug coverage tend to pay for all outpatient pharmaceuticals out-of-
pocket.  The variability is highly dependent on geographic location
and income level.
Sources: Australia:  Australian Bureau of Statistics. 1999.   “Australia Now: A Statistical Profile of Health.”  Germany:  Brown, L. & Volker, A.  1999.  “Manacled
competition: Market Reforms in German Health Care.”  Health Affairs. 18, 3, 76-91.  Evers, A. 1998.  “The New Long-Term Care Insurance Program in
Germany.”  Journal of Aging Social Policy.  10(1), 77-98.  Mahkorn, Deirdre T. 1999.  June 12, p536. Electronic British Medical Journal.  Rosian, Ingrid,
Habl, Claudia, and Volger, Sabine.  1998.  Pharmaceuticals:  Market Control in Nine European Countries.  Austrian Health Institute (OBIG).
Commissioned by the Federal Ministry of Labour, Health, and Social Affairs.  Japan:   Graig, Laurene A.  1999.  Health of Nations, 3rd ed.  Washington,
D.C.:  Congressional Quarterly Press.  Ikegami, Naoki, and John Creighton Campbell.  1999.  “Health Care Reform in Japan:  The Virtues of Muddling
Through.”  Health Affairs. 18 (3):  56-75.  Oliver, Adam James, Naoki Ikegami, and Shunya Ikeda.  1997.  "Japan's Aging Population:  Implications for
Healthcare."  Pharmacoeconomics.  11:  306-318.  New Zealand:   Health Funding Authoritie’s Funding Agreement with Minister of Health -Service
Coverage Document.  April 14, 1999.  Health Expenditure Trends in New Zealand:  1980-1998.  1999.  Ministry of Health, Wellington, New Zealand.
August.  Pharmaceutical Management Agency Ltd. 1999.  Annual Review for the Year Ended June 30, 1998.  PHARMAC:  Wellington, New Zealand.
United Kingdom:   Rosian, Ingrid, Habl, Claudia, and Volger, Sabine.  1998.  Pharmaceuticals:  Market Control in Nine European Countries.  Austrian
Health Institute (OBIG).  Commissioned by the Federal Ministry of Labour, Health, and Social Affairs.  United States:   Medicare Chart Book. 1998.
Washington, D.C.: Healthcare Financing Administration and Office of Strategic Planning, Department of Health and Human Services.  Pharmaceutical
Research and Manufacturers of America (PhRMA). 1999.  19 9 Pharmaceutical Industry Profile.  Washington D.C.: PhRMA.
Table 2.    Various Measures of Health Care and Drug Spending
in Seven Comparison Countries
Country
Percent GDP on
Health Care
(1997) Rank
Per Capita Health
Expenditure
(US$ PPP, 1997) Rank
United States Dollars
Per Capita
(1997) Rank
Australia 8.3 4 1, 805 4 N/A
Canada 9.3 3 2, 095 3 1,837 5
Germany 10.4 2 2, 339 2 2,677 2
Japan 7.3 6 1, 741 5 2,453 3
New Zealand 7.6 5 1, 352 6 2,114 4
United Kingdom 6.7 7 1, 347 7 1,457 6
United States 14.0 1 4, 090 1 4,090 1
Public Sector Health
Expenditures as Percent of
GDP (1997) Rank
Percent of Total Health
Expenditure on Drugs
(1996) Rank
Drug Spending
Per Capita
(PPP, 1996) Rank
Australia 5.7 5 11.4 6 202 6
Canada 6.4 3 12.5 5 258 4
Germany 8.1 1 12.7 4 289 3
Japan 5.7 5 20.8 1 349 1
New Zealand 5.8 4 15.2 3 194 7
United Kingdom 5.7 5 16.5 2 218 5
United States 6.5 2 8.8 7 344 2
Sources: OECD Health Data 98, A Comparative Analysis of 29 Countries.  Graig, Laurene A.  1999.  Health of Nations, 3rd ed.  Washington, D.C.:
Congressional Quarterly Press.
Table 3.    Aging and Population Data for the Seven Countries
Country
Total Population
(1998)
Percent of Population
Over Age 65
(1960)
Percent of Population
Over Age 65
(1997)
Projected Population
Over Age 65 in Year
(2020)
Percent of Population
in Workforce (1996)
Australia 18,520 8.5 12.1 20.6a 49.8
Canada 30,563 7.6 12.3 18.2 50.5
Germany 82,133 10.8 16.2 22.5 N/A
Japan 126,281 5.7 15.7 25.6 53.3
New Zealand 3,796 8.7 11.6 N/A 49.4
United Kingdom 58,649 11.7 15.7 19.7 48.2
United States 274,028 9.2 12.0 17.5 50.4
     aFor year 2016—Australian Bureau of Statistics (1990) Projections of the Populations of Australian States and Territories, 1989-2031.  Catalogue
#3222.0.
     N/A indicates not available.
Source: OECD Health Data 98, A Comparative Analysis of 29 Countries.  Graig, Laurene A.  1999.  Health of Nations, 3rd ed.  Washington, D.C.:
Congressional Quarterly Press.
Table 4.    Publicly Provided Access to and Coverage of Pharmaceuticals for the Elderly
Country
Proportion of Elderly
Covered for Drugs
Annual
Premiums
for Drugs Deductible for Drugs Cost Sharing for Drugs
Out-of-Pocket Annual
Maximum for Drugs
Reductions for: Low
Income, Chronic
Disease
Australia 100% of elderly are
covered
None. None. Fixed amount.  Pensioners
pay $3.20 per prescription.
(Receive pharmaceutical
allowance in pension to
defray some of cost).
Once total expenditures
exceed $166.40 for seniors in
a year, all prescriptions are
free.
Concession cards, health
care cards, children.
Canada 98% of elderly are
covered
Varies by
province from
$0 to $215.
Varies by province
and circumstance $0-
$1700.
Combination of fixed
indemnity payment and co-
insurance.
Half of provinces have
maximum.  Some fixed, some
income based.
Low income.
Germany 100% of elderly are
covered
Yes.  Based
on ability to
pay.
None. Based on pack size. Small
(5 DM), medium (9DM),
large (13 DM) fixed
amounts.
Co-pays must not be more
than 2% of patient income.
Those with chronic
disease must not pay
more than 1% of their
total income, welfare
recipients and those with
income below 1, 736
DEM are exempt.
Japan 100% (employer
mandated system)
Employer and
individual
premiums and
tax revenue.
No additional
premiums for drugs.
Co-payments are for the
visit to the doctor, not for
the drug.  Approximately
500 yen ($4 US)
Drug benefits are free if over
70.  If over 65, depends on
income, assets, household
size, demographics of city etc.
Approximately $530 US per
month is maximum – no
distinct between drugs and
visits.
Low income, chronically
ill, and seniors over age
70.
New
Zealand
100% of elderly are
covered
Yes.  Part of
expenditure
on premiums
is reimbursed.
N/A Fixed amount -15$ for
general population.  High
use and community services
card-holders all have
reduced co-pays.
High use of 20 or more listed
pharmaceuticals in one year.
High use health card,
community services card
holders.
Table 4.     Continued
Country
Proportion of Elderly
Covered for Drugs
Annual
Premiums
for Drugs Deductible for Drugs Cost Sharing for Drugs
Out-of-Pocket Annual
Maximum for Drugs
Reductions for: Low
Income, Chronic
Disease
United
Kingdom
100% of elderly are
covered
None. None
(65 $ US ‘seasons
ticket’, which can be
purchased annually.
Then you do not have
to pay any co-pay -is
that a deductible?)
Fixed amount – 5.8 pounds
for general population.
Seniors are exempt from co-
pays.
None. Children, low-income are
exempt from co-pays.
United
States
25% have coverage
through managed care,
and  Medicaid, (40%
have coverage through
other sources including
Medigap)
Varies by
plan.
Varies by plan and
drug
Varies by plan and drug. Varies by plan – most have a
maximum benefit and
individual cover cost over this
amount
Varies by state residence
and income status and
type of plan.
Sources: Australia:  Australian Bureau of Statistics. 1999.   “Australia Now: A Statistical Profile of Health.”  Germany:  Brown, L. & Volker, A.  1999.  “Manacled
competition: Market Reforms in German Health Care.”  Health Affairs. 18, 3, 76-91.  Evers, A. 1998.  “The New Long-Term Care Insurance Program in Germany.”
Journal of Aging Social Policy.  10(1), 77-98.  Mahkorn, Deirdre T. 1999.  June 12, p536. Electronic British Medical Journal.  Rosian, Ingrid, Habl, Claudia, and
Volger, Sabine.  1998.  Pharmaceuticals:  Market Control in Nine European Countries.  Austrian Health Institute (OBIG).  Commissioned by the Federal Ministry of
Labour, Health, and Social Affairs.  Japan:   Graig, Laurene A.  1999.  Health of Nations, 3rd ed.  Washington, D.C.:  Congressional Quarterly Press.  Ikegami, Naoki,
and John Creighton Campbell.  1999.  “Health Care Reform in Japan:  The Virtues of Muddling Through.”  Health Affairs. 18 (3):  56-75.  Oliver, Adam James,
Naoki Ikegami, and Shunya Ikeda.  1997.  "Japan's Aging Population:  Implications for Healthcare."  Ph macoeconomics.  11:  306-318.  New Zealand:  Health
Funding Authoritie’s Funding Agreement with Minister of Health -Service Coverage Document.  April 14, 1999.  Health Expenditure Trends in New Zealand:  1980-
1998.  1999.  Ministry of Health, Wellington, New Zealand. August.  Pharmaceutical Management Agency Ltd. 1999.  Annual Review for the Year Ended June 30,
1998.  PHARMAC:  Wellington, New Zealand.  United Kingdom:   Rosian, Ingrid, Habl, Claudia, and Volger, Sabine.  1998.  Pharmaceuticals:  Market Control in
Nine European Countries.  Austrian Health Institute (OBIG).  Commissioned by the Federal Ministry of Labour, Health, and Social Affairs.  United States:
Medicare Chart Book. 1998.  Washington, D.C.: Healthcare Financing Administration and Office of Strategic Planning, Department of Health and Human Services.
Pharmaceutical Research and Manufacturers of America (PhRMA). 1999.   Pharmaceutical Industry Profile.  Washington D.C.: PhRMA.
Glossary
Term Definition
Access An individual’s ability to obtain prescription insurance.
Brand Name Drug A drug manufactured by a specific drug company that is trademarked by that
company.  Drugs in the U.S. are generally patented for a certain amount of time
meaning no other firm can create a “generic” version of the drug until the
patent has expired.
Coverage The services, procedures, and/or medications available under a particular health
plan or insurance agreement.
Covered Services Specific medically related services that will be paid for (in part or in full) by a
health plan or insurance agreement.
Generic Drugs An identical drug to a brand-name drug that is produced once the patent is
expired.
Coinsurance A specific proportion or percentage of a prescription cost that an individual is
required to pay out-of-pocket for a specific drug.
Copayment A fixed indemnity fee per prescription that an individual is required to pay out-
of-pocket for a specific drug.
Cost Containment A variety of policies and techniques that governments and insurance companies
use to limit healthcare costs.
Cost Sharing The combinations of deductibles, copayments, coinsurance, and/or premiums
that an individual must contribute towards their healthcare and/or prescription
drug plan. [Do we want to include premiums in this definition?  I think most do
not.]
Deductible The dollar amount up to an agreed upon limit that an individual must pay for
covered services before a health plan or insurance agreement pays for any
healthcare costs, usually in an annual period.
Drug Utilization Review
(DUR)
A practice whereby an evaluation of drug prescribing practices and drug
utilization is conducted to determine the appropriateness of a particular drug.
[Need to get a formal definition, as this is too loose.]
First Dollar Coverage Coverage for all expenses without a deductible.
Formulary Also known as a positive list or schedule of benefits.  A list of prescription
drugs that the insurer is prepared to cover.
Generic Substitution A cost containment practice where generic drugs, where available, are
automatically substituted in place of brand name drugs.
Health Insurance A program that provides an individual with financial assistance to pay for
medical services.
Glossary (continued)
Term Definition
Health Plan A specific set of benefits that are available to an individual that accesses a
particular type of health insurance.
Last Dollar Coverage The amount of coverage for medical expenses paid by the insurer above a
(pre-determined) level of expenditure.
Managed Care Organization A term used to describe a variety of healthcare plans that are delivered by
an organization that monitors utilization, cost, and performance.
Maximum Benefit A cap on the dollar amount of benefits one can receive.
Means-testing A review of an individual’s income and/or assets the outcome of which
determines that individual’s eligibility for a particular health plan.
Negative List A list of prescription drugs which the insurer will not cover.
Out-of-pocket cost The amount that an individual must spend of their personal disposable
income on healthcare expenditures.
Over the Counter Drugs (OTC) A drug that does not require a prescription according to a particular
country’s laws.  In many countries, this refers to a drug which can be freely
sold without supervision of a pharmacist.
Pharmaceutical Benefit Management
(PBM) Organization
A organization that administers and reviews the usage of prescription drugs.
Positive List A list of prescription drugs that are included on a formulary that providers
can prescribe to patients.
Premium A fee that is paid by an individual for healthcare services regardless of
actual utilization.
Prescription Drug A drug that has been approved by a particular country's government and can
only be given to an individual pursuant to the issuing of a prescription by a
licensed professional.
Reference Based Pricing A pricing system that assigns the average or minimum price for a given
drug class to a new drug in that class.
Therapeutic Alternative A drug that is similar to another chemically and should have a similar effect
to the drug to which it is being compared.
Therapeutic Substitution The dispensing of a therapeutic alternative drug that is different from the
original drug prescribed.
Universal Access The availability of health insurance for every citizen and/or resident of a
country regardless of income.
31
References
Australian Bureau of Statistics.  1999.  “Australia Now:  A Statistical Profile of Health.”
http://www.statistics.gov.au/.  Copyright Commonwealth of Australia.
Barents Group.  1999.  “Analysis of Benefits Offered by Medicare HMOs, 1999:  Complexities
and Implications.”  Washington, DC:  Kaiser Family Foundation.
Brown, Lawrence and Amelung Volker.  1999.  “Managed Competition:  Market Reforms in
German Health Care,” Health Affairs. 18(3): 76-91.
Busse, Richard and Chris Howorth.  1996.  “Fixed Budgets in the Pharmaceutical Sector in
Germany:  Effects of Costs and Equity.”  In F.D. Schwartz, H. Glennerster, and R.B.
Saltman (eds.), Fixing Health Budgets:  Experience from Europe and North America.
London, UK:  John Wiley & Sons Ltd., pp. 109-25.
Cabana, Michael D., Cynthia S. Rand, Neil R. Powe, Albert W. Wu, Modena H. Wilson, Paul-
Andre C. Abboud, and Haya R. Rubin.  1999.  “Why Don't Physicians Follow Clinical
Practice Guidelines? A Framework for Improvement,” Journal of the American Medical
Association, 282(15): 1458-65.
Canadian Coordinating Office for Health Technology Assessment.  1994.  “Guidelines for
Economic Evaluation of Pharmaceuticals: Canada” 1st Edition.  Ottawa, Ontario, Canada:
author, November.
Commonwealth Department of Health, Housing, and Community Services.  1992.  “Guidelines
for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical
Benefits Advisory Committee.”  Canberra:  Australian Government Publishing Service.
August.
Davis, David A. and Anne Taylor-Vaisey.  1997.  “Translating Guidelines into Practice. A
Systematic Review of Theoretic Concepts, Practical Experience and Research Evidence
in the Adoption of Clinical Practice Guidelines,” Canadian Medical Association Journal,
157: 408-16.
Davis, Margaret, John Poisal, George Chulis, Carlos Zarabozo, and Barbara Cooper.  1999.
“Prescription Drug Coverage, Utilization, and Spending Among Medicare Beneficiaries,”
Health Affairs, 18(1): 231-243.
Deber, Raisa and William Swan.  1999.  “Canadian Health Expenditures: Where Do We Really
Stand Internationally?” Canadian Medical Association Journal,. 160: 1730-34.
Dingwall, David.  1997.  Drug Costs in Canada.  Ottawa. Industry Canada.
Evers, A.  1998.  “The New Long-Term Care Insurance Program in Germany,” Journal of Aging
Social Policy, 10(1): 77-98.
32
Feder, Gene, Martin, Richard Grol, Chris Griffiths, and Jeremy Grimshaw.  1999.  “Using
Clinical Guidelines,” British Medical Journal, 318: 728-30.
Feek, Colin M., Winston, McKean, Loek Henneveld, Graeme Barrow, Wendy Edgar, and Ron J.
Paterson.  1999. “Experience with Rationing Health Care in New Zealand.” British
Medical Journal, 318: 1346-48.
Fuchs, Victor R.  1998.  “Health Care for the Elderly:  How Much?  Who Will Pay for It?”
NBER Working Paper #6755.  Cambridge, MA.: National Bureau of Economic Research.
Gibson, Mary Jo, Normandy Brangan, David Gross, and Craig Caplan.  1999.  “How Much Are
Medicare Beneficiaries Paying Out-of-Pocket for Prescription Drugs?”  Washington,
D.C.:  American Association of Retired Persons (AARP), September.
Grimshaw, Jeremy, Nick Freemantle, Sheila Wallace, Ian Russell, Brian Hurwitz, Ian Watt,
Andrew Long, and Trevor Sheldon.  1995.  “Developing and Implementing Clinical
Practice Guidelines,” Quality in Health Care, 4: 55-64.
Graig, Laurene A.  1999.  Health of Nations, 3rd ed.  Washington, DC: Congressional Quarterly
Press.
Gross, David, Craig Caplan, and Mary Jo Gibson.  1998.  “FYI:  Estimates of Financial Burden
of Prescription Drugs on Beneficiaries in Medicare Fee-For-Service.”  Washington, DC:
American Association of Retired Persons (AARP), September.
Gross, David, and Sharon Bee.  1999.  “State Pharmacy Assistance Programs.”  Washington,
DC: American Association of Retired Persons (AARP), April.
Haycox, Alan, Adrian  Bagust, and Tom Walley.  1999. “Clinical GuidelinesThe Hidden
Costs,” British Medical Journal, 318: 391-3.
Health Care Financing Authority (HCFA).  1999.  “Medicare + Choice:  Policy Concerns,
Implications, and Prescription for Change.”  Washington, DC:  U. S. Department of
Health and Human Services.
Hurwitz, Brian.  1999.  “Legal and Political Considerations of Clinical Practice Guidelines,”
British Medical Journal, 318: 661-64.
Ikegami, Naoki and John Creighton Campbell.  1999.  “Health Care Reform in Japan:  The
Virtues of Muddling Through,” Health Affairs, 18(3): 56-75.
Levit, Katherine, Cathy Cowan, Bradley Braden, Jean Stiller, Arthur Sensenig, and Helen
Lazenby.  1998.  “National Health Expenditures in 1997:  More Slow Growth,” Health
Affairs, 17(6): 99-110.
Lillard, Lee A., Jeannette Rogowski, and Raynard Kington.  1999.  “Insurance Coverage for
Prescription Drugs:  Effects on Use and Expenditures in the Medicare Population,”
Medical Care, 37(9): 926-936.
33
Mahkorn, Deirdre T.  1999.  “New President of the German Medical Council May Back
Reform,” British Medical Journal, 318 (June 12): 1576
Majeed, Azeem and Malcolm, Laurence.  1999.  “Unified Budgets for Primary Care Groups.”
British Medical Journal, 318: 772-76.
Malcolm L. and N. Mays.  1999.  “New Zealand's Independent Practitioner Associations: A
Working Model of Clinical Governance in Primary Care?” British Medical Journal, 319:
1340-42.
Majeed, Azeem and Laurence Malcolm.  1999.  “Unified Budgets for Primary Care Groups,
British Medical Journal, 318: 772-776.
National Pharmaceutical Council, Inc.  1998.  “Pharmaceutical Benefits Under State Medical
Assistance Programs.”  Reston, VA:  The National Pharmaceutical Council, Inc.,
December.
New Zealand Ministry of Health.  1999.  “Health Funding Authoritie’s Funding Agreement with
Minister of Health.”  Wellington, NZ:  Ministry of Health, April.
New Zealand Ministry of Health.  1999.  “Health Expenditure Trends in New Zealand: 1980-
1998.”  Wellington, NZ:  Ministry of Health, August.
Oliver, Adam James, Naoki Ikegami, and Shunya Ikeda.  1997.  “Japan's Aging Population:
Implications for Healthcare,” Pharmacoeconomics, 11: 306-318.
Organization for Economic Cooperation and Development.  1998.  OECD Health Data 98.  A
Comparative Analysis of 29 Countries.  Paris:  OECD.
Pharmaceutical Management Agency Ltd.  1999.  Annual Review for the Year Ended June 30,
1998.  Wellington, NZ: PHARMAC.
Pharmaceutical Research and Manufacturers of America (PhRMA). 1999.   Pharmaceutical
Industry Profile.  Washington DC: PhRMA.
Rosian, Ingrid, Claudia Habl, and Sabine Volger.  1998.  Pharmaceuticals:  Market Control in
Nine European Countries.  Austrian Health Institute (OBIG).  Commissioned by the
Federal Ministry of Labour, Health, and Social Affairs.  Vienna, Austria:  OBIG,
Austrian Health Institute.
Rother, John.  1999.  “A Drug Benefit:  The Necessary Prescription for Medicare,” Health
Affairs, 18(4): 20-22.
Schulenburg, J.-Matthias Graf Von Der.  1997.  “Management of Cost and Utilization of
Pharmaceuticals in Germany,” Health Policy, 41 (supplement): s45-s53.
34
Seddon Mary and Colin Feek.  1999.  “Rationing Health Care in New Zealand:  Explicit
Rationing Needs More Debate” [letter], British Medical Journal, 319: 708.
Soumerai, Stephen B. and Dennis Ross-Degnan.  1999.  “Inadequate Prescription-Drug
Coverage for Medicare Enrollees—A Call to Action,” The New England Journal of
Medicine, 340(9): 722-28.
Tuffs, Annette.  1999. “Germany Fails to Introduce Drugs ‘Blacklist’,” British Medical Journal,
318: 1232.
Tuffs, Annette.  1999.  “German Doctors are Unhappy about Drugs Budget,” British Medical
Journal, 319: 536.
Tuffs, Annette.  1999.  “German Government Breaks Off Talks with Doctors,” B itish Medical
Journal, 319: 874.
U. S. Government Accounting Office (GAO).  1999.  “Medicare Beneficiaries’ Prescription
Drug Coverage,” Testimony Before the Subcommittee on Health and Environment,
Committee on Commerce, House of Representatives:  Statement of Laura A. Dummit,
Associate Director, Health Financing and Public Health Issues, Health Education, and
Human Services Division.  Washington, DC, September 28.
U.S. Department of Health and Human Services.  1998.  Medicare Chart Book.  Washington,
D.C.: Healthcare Financing Administration and Office of Strategic Planning.
(www.ncfa.gov/pubforms/chartbk.htm).
Willison Donald J., Paul V. Grootendorst, and Jeremiah Hurley.  2000.  “Variation in
Pharmacare Coverage Across Canada,” Health Affairs (submitted).
Wilson, Robert P.H., Iain Buchan, T. Walley.  1995.  “Alterations in Prescribing by General
Practitioner Fundholders: an Observational Study,” British Medical Journal, 311:
1347-50.
Wilton, Paula and Richard D. Smith.  1998.  “Primary Care Reform: A Three Country
Comparison of 'Budget Holding',” Health Policy,  44: 149-66.
Woolf, Steven H., Richard Grol, Allen Hutchinson, Martin Eccles, and Jeremy Grimshaw.  1999.
“Clinical Guidelines. Potential Benefits, Limitations, and Harms of Clinical Guidelines,”
British Medical Journal, 318: 527-30.
